Iovance Biotherapeutics, Inc. (IOVA)

NGM – Цена в реальном времени. Валюта: USD

3.56

-0.14 (-3.78%)

При закрытии: May 12, 2026, 4:00 PM EDT

3.60

+0.04 (1.12%)

До открытия: May 13, 2026, 4:00 AM EDT

08.05.2026

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.

08.05.2026

Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity

Iovance Biotherapeutics, Inc. markets Amtagvi, a TIL therapy for advanced melanoma, and just reported Q1 earnings. Following Q1 results, IOVA shares declined over 13%, closing at $3.55, with a market cap of $1.59bn. The earnings announcement triggered a notable sell-off, reflecting investor concerns about near-term performance.

07.05.2026

Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript

07.05.2026

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.19 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.36 per share a year ago.

07.05.2026

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

1Q26 Total Revenue of ~$71M Delivers ~ 45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous Endometrial Cancer SAN CARLOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2026 financial results, business achievements, and corporate updates.

30.04.2026

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

28.04.2026

Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out

Iovance Biotherapeutics is rated a BUY following Replimune's exit, solidifying IOVA's lead in post-PD-1 melanoma. IOVA's lifileucel shows best-in-class ORR in earlier-line melanoma and promising efficacy in NSCLC, with a strong clinical pipeline and upcoming catalysts. Commercial ramp of lifileucel is underway, with 2025 sales at $220M and gross margins improving to 50%, but operational and adoption hurdles persist.

Видео

No Data

There is no data to display

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
IOVA	UBS	Neutral	undefined >> $2	May 16th 2025
IOVA	Truist	Hold	undefined >> undefined	May 12th 2025
IOVA	Citizens JMP	Market Perform	undefined >> undefined	May 9th 2025

Пресс-релизы

07.05.2026

Iovance Biotherapeutics, Inc. (IOVA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Iovance Biotherapeutics, Inc. (IOVA)

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity

Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity

Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

Search stocks

Iovance Biotherapeutics, Inc. (IOVA)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Iovance Biotherapeutics, Inc. (IOVA)

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity

Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity

Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Iovance Biotherapeutics: Buy, Because Short-Term Competitor Is Out

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas